Mild cognitive impairment (MCI) - a common precursor of Alzheimer's type dementia, causes a slight but noticeable and measurable decline in cognitive abilities, including memory and thinking skills.
Clinicians should recommend exercise and cognitive training for patients with MCI. This is according to new guidelines published in the online issue of Neurology®, the medical journal of the American Academy of Neurology. The panel also suggests there is little evidence that cholinesterase inhibitors — medications used to treat Alzheimer's dementia— are effective in persons with MCI.
Detecting Alzheimer’s the Non-invasive Way
Volume change in brain region linked to physiological changes characteristic of Alzheimer's disease.
Advertisement
‘With early identification, diagnosis, and education, care for persons with mild cognitive impairment continues to evolve.’
Tweet it Now
The AAN convened a panel of experts in the field to review literature on the prevalence, prognosis and treatment of MCI, to update the earlier 2001 AAN guidelines. Dan Marson, Ph.D., J.D., professor emeritus in the Department of Neurology, School of Medicine at the University of Alabama at Birmingham, was a member of that panel and is a co-author of the new guidelines.
The panel confirmed that MCI is common in older populations, and its prevalence increases with age and with lower educational level. Persons with MCI are at higher risk of progressing to dementia than are age-matched controls.
![Education Reduces Risk of Alzheimer’s - Research Found]( "Education Reduces Risk of Alzheimer’s - Research Found")
Education reduces risk of Alzheimer's disease, genetic research at the University of Cambridge found evidence. Education helps improve brain wiring and networks
"The panel addressed four basic questions," Marson said. "What is the prevalence of MCI in the general population? What is the prognosis for patients diagnosed with MCI for progression to a diagnosis of dementia, and how does this compare with an age-matched general population? What pharmacologic treatments are effective for patients diagnosed with MCI? And what nonpharmacologic treatments are effective for patients diagnosed with MCI?"
Among the panels' recommendations:
Clinicians should assess for MCI with validated tools in appropriate scenarios.
Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms.
Clinicians should monitor cognitive status of patients with MCI over time.
Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated.
Clinicians may choose not to offer cholinesterase inhibitors; if offering, they must first discuss lack of evidence.
Clinicians should recommend regular exercise.
Clinicians may recommend cognitive training.
Clinicians should discuss diagnosis, prognosis, long-term planning and the lack of effective medicine options and may discuss biomarker research with patients with MCI and families.
"Care for persons with MCI continues to evolve, with early identification, diagnosis, and education important to patients with MCI and their families," said Marson. "Where clinicians are not proficient in caring for the cognitive and behavioral or psychiatric needs of persons with MCI, referral to appropriate specialists is an important part of the treatment paradigm in line with the guideline recommendations."
The AAN panel was led by Ronald C. Petersen, M.D., Ph.D., at the Mayo Clinic. Other panelists represented the University of Pittsburgh, University of Florida, Heart Rhythm Society, Charleston Area Medical Center, University of Kansas, University of Calgary, Washington University, University of Wisconsin and the Cleveland Clinic.
Source: Newswise
Education Reduces Risk of Alzheimer’s - Research Found
Education reduces risk of Alzheimer's disease, genetic research at the University of Cambridge found evidence. Education helps improve brain wiring and networks
Advertisement
"The panel addressed four basic questions," Marson said. "What is the prevalence of MCI in the general population? What is the prognosis for patients diagnosed with MCI for progression to a diagnosis of dementia, and how does this compare with an age-matched general population? What pharmacologic treatments are effective for patients diagnosed with MCI? And what nonpharmacologic treatments are effective for patients diagnosed with MCI?"
Among the panels' recommendations:
Clinicians should assess for MCI with validated tools in appropriate scenarios.
Clinicians should evaluate patients with MCI for modifiable risk factors, assess for functional impairment, and assess for and treat behavioral/neuropsychiatric symptoms.
Clinicians should monitor cognitive status of patients with MCI over time.
Cognitively impairing medications should be discontinued where possible and behavioral symptoms treated.
Clinicians may choose not to offer cholinesterase inhibitors; if offering, they must first discuss lack of evidence.
Clinicians should recommend regular exercise.
Clinicians may recommend cognitive training.
Clinicians should discuss diagnosis, prognosis, long-term planning and the lack of effective medicine options and may discuss biomarker research with patients with MCI and families.
"Care for persons with MCI continues to evolve, with early identification, diagnosis, and education important to patients with MCI and their families," said Marson. "Where clinicians are not proficient in caring for the cognitive and behavioral or psychiatric needs of persons with MCI, referral to appropriate specialists is an important part of the treatment paradigm in line with the guideline recommendations."
The AAN panel was led by Ronald C. Petersen, M.D., Ph.D., at the Mayo Clinic. Other panelists represented the University of Pittsburgh, University of Florida, Heart Rhythm Society, Charleston Area Medical Center, University of Kansas, University of Calgary, Washington University, University of Wisconsin and the Cleveland Clinic.
Source: Newswise
Two Tau Proteins That Aggravate Alzheimer’s Disease Identified
Individual Tau proteins interact with and disrupt the cell membrane of neurons.
Advertisement
 Psychoactive Drugs For Alzheimer’s Can Increase Risk of DeathBenzodiazepines and related drugs are frequently used in the treatment of anxiety, agitation, and insomnia in persons with dementia. | Advertisement
|
Advertisement
Latest Research News
New study findings delineate how aging affects the immune response following Spinal cord injury (SCI) and highlight the participation of the spinal cord meninges in repair.
A recent clinical trial suggests that the first medication therapy to reduce the progression of nearsightedness in children could be on the way.
Autoimmune disorders were found to be linked to Sjogren's, systemic lupus erythematosus, and systemic sclerosis.
Successful brain pacemaker implantation has helped a 51year old Parkinson's disease patient to revitalize her quality of life.
Recent recommendations on lifestyle behaviors to prevent progression of rheumatic and musculoskeletal diseases revealed.